Bryan J. Luchs

Recent matters include the representation of:

• Falcon Capital Acquisition Corp. (NASDAQ: FCAC), a SPAC, in its US$3.9 billion business combination with Sharecare, Inc., a digital health company based in Georgia.
• InterPrivate III Financial Partners Inc. (NYSE: IPVF), a SPAC, in its US$2.3 billion acquisition of Aspiration Partners, Inc., a global leader in Sustainability as a Service solutions for consumers and companies.
• DFP Healthcare Acquisitions Corp. (NASDAQ: DFPH, DFPHW), a SPAC, in its US$842 million business combination with The Oncology Institute, a US market-leader in value-based oncology care.
• Deerfield Healthcare Technology Acquisitions Corp. (NASDAQ: DFHT), a SPAC, in its US$614 million business combination with CareMax Medical Group, L.L.C. and IMC Medical Group Holdings LLC, creating a technology-enabled care platform providing value-based care and chronic disease management to seniors.
• FS Development Corp. II (NASDAQ: FSII), a SPAC, in its US$276.2 million business combination with Pardes Biosciences, Inc., an early stage biopharmaceutical company developing a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.
• Helix Acquisition Corp. (NASDAQ: HLXA), a SPAC, in its US$230 million business combination with MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases.
   
• FS Development Corp. (NASDAQ: FSDC), a SPAC, in its US$216 million business combination with Gemini Therapeutics, Inc., a clinical stage precision medicine company developing treatments for genetically defined age-related macular degeneration.
• Lantheus Holdings, Inc. (NASDAQ: LNTH) in its acquisition of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX).
• Roche Diagnostics Corp. in the sale of Roche Health Solutions Inc. to CardioNet, LLC, a wholly owned subsidiary of BioTelemetry, Inc.
• Hikma Pharmaceuticals PLC in its US$2.65 billion acquisition of the US-based generic drugs businesses, Roxane Laboratories and Boehringer Ingelheim Roxane, from German drug maker Boehringer Ingelheim.
• Hikma Pharmaceuticals PLC in its acquisition of assets relating to a portfolio of six injectable products for commercialization in certain European markets from Pfizer.
• Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a world leader in musculoskeletal health solutions, in its US$14 billion deal to acquire Biomet, Inc., one of the world's leading medical device manufacturers.
• Omnicare, Inc. in its US$12.7 billion acquisition by CVS Health, as well as Omnicare's prior US$1.8 billion unsolicited acquisition of NeighborCare Inc. and US$460 million unsolicited acquisition of NCS HealthCare, Inc.
• Sony Corporation of America in its US$2.2 billion acquisition of EMI Music Publishing with a consortium of acquirors; acquisition of the 50% interest in Sony/ATV Music Publishing LLC held by the Estate of Michael Jackson.
• King Pharmaceuticals, Inc. in its US$1.6 billion unsolicited acquisition of Alpharma Inc.
• Roivant Sciences Ltd. on several portfolio company transactions.
• Certares LP, a private equity group with a focus in the travel, transportation and hospitality industry, in the acquisition of 50 percent of the equity of AmaWaterways, a premium European river cruise operator; and in its acquisition of Guardian Alarm, a super-regional security provider.
• Special Committee of the Board of Directors of GFI Group Inc., (NYSE: GFIG), the New York brokerage and clearing house, in the successful completion of a tender offer by BGC Partners, Inc. (NASDAQ: BGCP), a leading global brokerage company servicing the financial and real estate markets, for the outstanding shares of GFI, resulting in an equity value of approximately US$780 million and an enterprise value of US$1 billion. The transaction marks one of the most complex hostile M&A transactions.
• J.F. Hillebrand USA Holding, Inc., a portfolio company of Cobepa SA (the Belgian investment company), in its acquisition of a majority of the outstanding equity interests of Satellite Logistics Group, a leading beverage supply chain logistics business.
• Nordic Capital, DLJ Merchant Banking, Avista Capital and other private equity sponsors in their US$1.525 billion sale of Fougera Pharmaceuticals to Sandoz.
• Nestlé México, SA de CV in its acquisition of a majority stake in Terrafertil, a company selling natural, organic, plant-based foods and healthy snacks.